Syneos Health (NASDAQ: SYNH) has announced its quarterly results on Thursday, August 2. The company reported $ 0.62 per share for the quarter, in addition to the $ 0.61 consensus estimate with $ 0.01, Bloomberg Earnings reports. The company had sales of $ 1.07 billion for the quarter compared with analyst estimates of $ 1.09 billion. Syneos Health had a negative net margin of 4.32% and a positive return on equity of 7.80%. The quarterly turnover of the company increased by 315.5% compared to the same quarter last year. Syneos Health has updated the FY18 guidance to $ 2.84-3.10 EPS.
SYNH opened Friday at $ 49.05. Syneos Health has a twelve month low of $ 31.10 and a twelve month high of $ 59.80. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 1.01. The company has a market capitalization of $ 5.02 billion, a PE ratio of 25.28, a PEG ratio of 1.16 and a beta of 0.83.
SYNH has been the subject of a number of research reports. Barclays repeated a "hold" classification and published a price target of $ 51.00 (higher than $ 43.00) on Syneos Health shares in a research report on Friday, August 3. Mizuho repeated a "hold" valuation and published a $ 51.00 price target on Syneos Health shares in a study letter on Monday, August 6th. ValuEngine increased shares of Syneos Health from a "sell" rating to a "hold" rating in a report on Thursday, July 5. Zacks Investment Research increased the shares of Syneos Health from a & # 39; hold & # 39; credit to a & # 39; buy & # 39; rating and set a price target of $ 47.00 for the company in a report on Wednesday, May 16. Finally, SunTrust Banks reissued a "buy" rating and published a price target of $ 60.00 on Syneos Health shares in a report on Friday, August 3. Three investment analysts assessed the shares with a hold rating and nine awarded a buy rating to the company. The stock currently has an average rating of & # 39; Buy & # 39; and an average price target of $ 52.78.
In other news: major shareholder H. Lee Equity Fund Vi Thomas sold 6,000,000 shares of the share in a transaction on Thursday 9 August. The shares were sold at an average price of $ 49.73 for a total transaction of $ 298,380,000.00. The transaction was disclosed in a legal application to the Securities & Exchange Commission, which is available through the SEC website. Business mixers own 0.57% of the company's shares.
About Syneos Health
Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia Pacific region and Latin America. It works through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning phase I through phase IV, including global full-service studies, as well as unbundled services such as clinical monitoring, recruitment of researchers, patient recruitment, data management and tutoring to help customers with the development process of medicines.
Recommended story: fundamental analysis – how it helps investors
Receive news and ratings for Syneos Health Daily – Enter your email address below to receive a concise, daily summary of the latest news and analyst ratings for Syneos Health and related companies with the FREE daily email newsletter from MarketBeat.com.